Founding Editor
G. Mathé

Cancer Immunology Immunotherapy

Other Biological Response Modifications

Volume 31 1990

Editors in Chief

R. W. Baldwin **E. Mihich**

Editorial Board

R. Arnon Rehovot
S. Ben-Efraim Tel Aviv
J. Bennett Albany, NY
N. Bloksma Utrecht
H. Blythman Basel
V. S. Byers Berkeley, CA
T. Carey Ann Arbor, MI
M. Cheever Seattle, WA
M. Colnaghi Milan
S. Dray Chicago, IL
S. Eccles Sutton, Surrey
M. J. Ehrke Buffalo, NY
E. Grimm Houston, TX
K. Hellström Seattle, WA
K. Höffken Essen
A. Houghton New York, NY
J. Kieler Copenhagen
H. Kirchner Heidelberg
E. Kleinerman Houston, TX
W. Knapp Vienna
H. Kobayashi Sapporo
M. Mastrangelo Philadelphia, PA
J. McVie London
M. Mitchell Los Angeles, CA
M. Moore London
R. J. North Saranac Lake, NY
G. Parmiani Milan
M. Price Nottingham
R. Rees Sheffield
R. A. Reisfeld La Jolla, CA
H.-J. Senn St. Gallen
K. Sikora London
Z. Steplewski Philadelphia, PA
G. Stevenson Southampton
J. Talmadge King of Prussia, PA
E. Tsubura Osaka
A. Uchida Kyoto
F. Vánky Stockholm
E. Vitetta Dallas, TX
B. Vose Cheshire

Springer International

Cancer Immunology Immunotherapy

Other Biological Response Modifications

This journal was founded in 1976. Founding editor: G. Mathé
Editors: R. W. Baldwin, E. Mihich
Published by Springer International

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e. g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U. S. Copyright Law, provided a fee is paid. This fee is US $ 0.20 per page, or a minimum of US $ 1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäß bei Augsburg

© Springer-Verlag Berlin Heidelberg 1990

Contents of volume 31

No. 1 (pp 1- 64) published 12 February 1990
No. 2 (pp 64-128) published 4 April 1990
No. 3 (pp 129-196) published 2 May 1990
No. 4 (pp 197-260) published 5 July 1990
No. 5 (pp 261-324) published 12 July 1990
No. 6 (pp 325-386) published 9 August 1990

Acknowledgement to Reviewers 128
Advani SH → Rajaram N
Ahrenkiel V → Ottesen SS
Ahsan CR → Sasaki J-i
Al-Azzawi F → Gallagher G
Arroyo PJ, Bash JA, Wallack MK: Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon α in a murine hepatic metastasis model 305
Austin EB → Durrant LG

Baldwin RW → Durrant LG
Baldwin RW → Price MR
Ballantyne KC → Durrant LG
Barker E → Weiskirch LM
Barrett JS, Wahl RL, Wagner JG, Brown R, Fisher SJ: Investigations into the route of uptake and pharmacokinetics of intraperitoneally administered monoclonal antibodies: I. Transdiaphragmatic blockade of the terminal lymphatics in the rat 365
Barrett SK → Hoover SK
Bar S → Weiss L
Bash JA → Arroyo PJ
Bassi C → Rodolfo M
Battisto JR → Gregorian SK
Bear HD → Hoover SK
Belldegrun A, Kasid A, Uppenkamp M, Rosenberg SA: Lymphokine mRNA profile and functional analysis of a human $CD4^+$ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid 1
Benczúr M → Stuber G
Beuvink A → Steerenberg PA
Blamey RW → Price MR
Blomgren H, Hallström M: Possible role of acrolein in oxazaphosphorine-induced enhancement of immunological reactivity 221
Bonmassar E → D'Onofrio C
Borkenhagen K → Sutherland F
Brandon DR → Smith W
Brown R → Barrett JS
Bryant LD → Sutherland F
Bugis SP, Lotzová E, Savage HE, Hester JP, Racz T, Sacks PG, Schantz SP: Inhibition of lymphokine-activated killer cell generation by blocking factors in sera of patients with head and neck cancer 176
Bulgarini D → Testa U
Burnett WV → Kerr DE

Calió R → D'Onofrio C
Callahan R → Primus FJ
Care A → Testa U
Chiba I → Okada F
Chong AS-F, Ybarrondo B, Grimes WJ, Hersh EM, Scuderi P: Phenotypic analyses of lymphokine-activated killer cells that release interferon γ and tumor necrosis factor α 255
Ciprani F → D'Onofrio C
Clarke AJ → Price MR
Cobbold S → Weiss L
Cohen SA → Maccubbin DL
Corvalan JRE → Smith W
Cranstone SA → Smith W

Damsma O → Mulder PHM de
De Boer EC → De Jong WH
Debruyne FMJ → De Jong WH
Debruyne FMJ → Mulder PHM de
De Jong WH, De Boer EC, Van Der Meijden APM, Vegt P, Steerenberg PA, Debruyne FMJ, Ruitenberg EJ: Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin 182
De Jong WH → Steerenberg PA
Den Otter W → Steerenberg PA
Ding L-N, Isobe K-i, Yoshida T, Kawashima K, Nakashima I: Induction of high-grade anti-tumor immunity by use of a recombinant $H\text{-}2K^b$/avian erythroblastosis virus erbB gene transfectant 115
Doesburg WH → Mulder PHM de
D'Onofrio C, Pesce CD, Fontana T, Ciprani F, Bonmassar E, Calió R: Modulation of the cell-mediated immune function by interferon α, β or γ can partially reverse the immunosuppression induced by human T-cell leukemia virus I in human cord blood cultures 213
Durrant LG, Robins RA, Ballantyne KC, Austin EB, Baldwin RW: Production of a human monoclonal antibody recognising a determinant on mouse IgG2b from a patient receiving mouse monoclonal antibody for diagnostic imaging 226

Edwards CL → Lotzová E
Ehrke MJ → Maccubbin DL
Eisenthal A, McIntosh JK: Effect of recombinant human tumor necrosis factor α on the induction of antibody-dependent cellular cytotoxicity in the treatment of established B16 melanoma liver nodules 243
Eisenthal A: Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2 342
Ershler WB → Ho S-P

Fagioli M → Testa U
Findlay J → Gallagher G
Fisher SJ → Barrett JS
Fitzgibbon L → Maghazachi AA
Flahart RE → Liao S-K
Foglesong PD → Winkler MA
Fontana T → D'Onofrio C
Fossati C → Testa U
Franssen MPH → Mulder PHM de
Freedman RS → Lotzová E
Fujimoto T → Uchida A
Fujimura T → Torisu M

Gaag R van der → Liao S-K
Gallagher G, Stimson WH, Findlay J, Al-Azzawi F: Interleukin-6 enhances the induction of human lymphokine-activated killer cells 49
Gallily R → Sher T
Gangal SG → Rajaram N
Geboers ADH → Mulder PHM de
Geerse E → Steerenberg PA
Giannella G → Testa U
Goldenberg DM → Shih LB
Gore VA → Smith W
Grazioli L → Sensi M
Greer JM, Halliday WJ: Comparison of T suppressor factors from tumour-bearing mice and mice immunized with a monoclonal anti-idiotypic antibody 151
Gregorian SK, Battisto JR: Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources 325
Gregorian SK, Battisto JR: Immunosuppression in murine renal cell carcinoma. II. Identification of responsible lymphoid cell phenotypes and examination of elimination of suppression 335
Grimes WJ → Chong AS-F

Habetswallner D → Testa U
Halliday WJ → Greer JM
Hallström M → Blomgren H
Hamada J-i → Takeichi N
Hank JA, Weil-Hillman G, Surfus JE, Sosman JA, Sondel PM: Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo 53
Hasegawa J → Okada F
Hausner P → Vorechovsky I
Hayashi Y → Torisu M
Hellström I → Kerr DE
Hellström KE → Kerr DE
Hersh EM → Chong AS-F
Hester JP → Bugis SP
Hilgers J → Liao S-K
Hirschberg DL → Kerr DE
Ho S-P, Kramer KE, Ershler WB: Effect of host age upon interleukin-2-mediated anti-tumor responses in a murine fibrosarcoma model 146
Ho P-C, Wong L-C, Lawton JWM, Ma H-K: A controlled trial of Bestatin in hydatidiform mole 187
Hoover SK, Barrett SK, Turk TMT, Lee T-C, Bear HD: Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity 121

Horton L → Liao S-K
Hosokawa M → Okada F
Hutzell P → Primus FJ

Isacchi G → Testa U
Ishikawa M → Okada F
Ishimitsu T → Torisu M
Isobe K-i → Ding L-N
Iwasaki K → Torisu M

Jägerroos H → Laatikainen A
Junghans RP: A strategy for evaluating lymphokine activation and novel monoclonal antibodies in antibody-dependent cell-mediated cytotoxicity and effector cell retargeting assays 207

Kaneda K → Natsuhara Y
Karjalainen H → Laatikainen A
Kashmiri S → Primus FJ
Kasid A → Belldegrun A
Katano M → Torisu M
Kato Y → Natsuhara Y
Kawashima K → Ding L-N
Kerr DE, Senter PD, Burnett WV, Hirschberg DL, Hellström I, Hellström KE: Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide 202
Kieler J → Ottesen SS
Kimbro B → Liao S-K
Kimura Y → Torisu M
Klein E → Vánky F
Klein E → Stuber G
Knüsli C → Landmann R
Kobayashi H → Takeichi N
Kobayashi H → Okada F
Komatsu T → Yamasaki H
Kondo M → Torisu M
Kramer KE → Ho S-P
Krempel H → Matzku S
Kunz Ch → Rasoul-Rockenschaub S

Laatikainen A, Karjalainen H, Jägerroos H, Sarkkinen H, Mäntyjärvi R: Tumorigenicity and H-2 expression of papillomavirus-transformed mouse cell lines 164
Lafreniere R → Sutherland F
Landmann R, Wesp M, Ludwig C, Obrist R, Knüsli C, Obrecht JP: Recombinant interferon γ up-regulates in vivo and down-regulates in vitro monocyte CD14 antigen expression in cancer patients 292
Lawton JWM → Ho P-C
Lee T-C → Hoover SK
Liao S-K, Flahart RE, Kimbro B, Horton L, Oldham RK, Hilgers J, Gaag R van der: Human tumor and normal tissue reactivity of the anti-(breast cancer) monoclonal antibody BA-Br-3 and its similarity to the anti-(epithelial membrane antigen) monoclonal antibody E29 65
Litzman J → Vorechovsky I
Li X → Takeichi N
Lokaj J → Vorechovsky I
Lotzová E, Savary CA, Freedman RS, Edwards CL, Morris M: Comparison of recombinant-interleukin-2-activated peripheral blood and tumor-infiltrating lymphocytes of patients with epithelial ovarian carcinoma: cytotoxicity, growth kinetics and phenotype 169
Lotzová E → Bugis SP
Ludwig C → Landmann R
Lynch DN → Smith W

Maccubbin DL, Cohen SA, Ehrke MJ: Indomethacin modulation of Adriamycin-induced effects on multiple cytolytic effector functions 373
Maghazachi AA, Fitzgibbon L: Fate of intravenously administered rat lymphokine-activated killer cells labeled with different markers 139
Ma H-K → Ho P-C
Manabe Y → Yamasaki H
Mäntyjärvi R → Laatikainen A
Masciulli R → Testa U
Masucci G, Ragnhammar P, Wersäll P, Mellstedt H: Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A) 231
Matzku S, Krempel H, Weckenmann H-P, Schirrmacher V, Sinn H, Stricker H: Tumour targeting with antibody-coupled liposomes: failure to achieve accumulation in xenografts and spontaneous liver metastases 285
McIntosh JK → Eisenthal A
Mellstedt H → Masucci G
Mizutani Y → Uchida A
Mokyr MB → Weiskirch LM
Montesoro E → Testa U
Morecki S → Weiss L
Morris M → Lotzová E
Mulder PHM de, Debruyne FMJ, Franssen MPH, Geboers ADH, Strijk S, Reintjes AGM, Doesburg WH, Damsma O: Phase I/II study of recombinant interferon α and γ in advanced progressive renal-cell carcinoma 321
Müller Ch → Rasoul-Rockenschaub S

Naik SL → Rajaram N
Nakamura Y → Okada F
Nakashima I → Ding L-N
Narita S → Sasaki J-i
Natsuhara Y, Oka S, Kaneda K, Kato Y, Yano I: Parallel antitumor, granuloma-forming and tumor-necrosis-factor-priming activities of mycoloyl glycolipids from *Nocardia rubra* that differ in carbohydrate moiety: structure-activity relationships 99
Nomoto K → Torisu M

Obrecht JP → Landmann R
Obrist R → Landmann R
Okada F, Hosokawa M, Hasegawa J, Ishikawa M, Chiba I, Nakamura Y, Kobayashi H: Regression mechanisms of mouse fibrosarcoma cells after in vitro exposure to quercetin: diminution of tumorigenicity with a corresponding decrease in the production of prostaglandin E_2 358
Okamoto E → Yamasaki H
Oka S → Natsuhara Y
Oldham RK → Liao S-K
O'Sullivan C → Price MR
Ottesen SS, Ahrenkiel V, Kieler J: Recombinant human interferon γ exerts an antiproliferative effect and modulates the expression of human leukocyte antigens A, B, C and DR in human urothelial cell lines 93

Parmiani G → Rodolfo M
Parmiani G → Sensi M
Patarroyo M → Vánky F
Pelicci PG → Testa U
Pendurthi TK → Primus FJ
Pesce CD → D'Onofrio C
Peschle C: Interleukin-2-dependent long-term cultures of low-density lymphocytes allow the proliferation of lymphokine-activated killer cells with natural killer, Tiγ/δ or TNK phenotype 11
Peschle C → Testa U
Poch T → Vorechovsky I
Pócsik E → Stuber G
Popow-Kraupp T → Rasoul-Rockenschaub S
Price JO → Winkler MA
Price MR, Clarke AJ, Robertson JRF, O'Sullivan C, Baldwin RW, Blamey RW: Detection of polymorphic epithelial mucins in the serum of systemic breast cancer patients using the monoclonal antibody, NCRC-11 269
Primus FJ, Pendurthi TK, Hutzell P, Kashmiri S, Slavin DC, Callahan R, Schlom J: Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells 349

Racz T → Bugis SP
Ragnhammar P → Masucci G
Rajaram N, Tatake RJ, Advani SH, Naik SL, Gangal SG: Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia 44
Rasoul-Rockenschaub S, Zielinski CC, Müller Ch, Tichatschek E, Popow-Kraupp T, Kunz Ch: Viral reactivation as a cause of unexplained fever in patients with progressive metastatic breast cancer 191
Reintjes AGM → Mulder PHM de
Robertson JFR → Price MR
Robins RA → Durrant LG
Rodolfo M, Salvi C, Bassi C, Parmiani G: Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model 28
Rodolfo M → Sensi M
Rosenberg SA → Belldegrun A
Rottem S → Sher T
Ruitenberg EJ → De Jong WH
Ruitenberg EJ → Steerenberg PA

Sacks PG → Bugis SP
Salvi C → Rodolfo M
Sarkkinen H → Laatikainen A
Sasaki J-i, Tamagake T, Narita S, Ahsan CR: Idiotype vaccine for tumor by anti-idiotypic antibody prepared against anti-(bacillus Calmette Guèrin) BCG monoclonal antibody 273
Savage HE → Bugis SP
Savary CA → Lotzová E
Schantz SP → Bugis SP
Scheper RJ → Steerenberg PA
Schirrmacher V → Matzku S
Schlom J → Primus FJ
Scuderi P → Chong AS-F
Sensi M, Grazioli L, Rodolfo M, Parmiani G: Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors 37
Senter PD → Kerr DE
Sher T, Rottem S, Gallily R: *Mycoplasma capricolum* membranes induce tumor necrosis factor α by a mechanism different from that of lipopolysaccharide 86
Shih LB, Goldenberg DM: Effects of methotrexate-carcinoembryonic-antigen-antibody immunoconjugates on GW-39 human tumors in nude mice 197
Shinka S → Yamasaki H
Sinn H → Matzku S
Slavin DC → Primus FJ
Slavin S → Weiss L
Smith W, Gore VA, Brandon DR, Lynch DN, Cranstone SA, Corvalan JRE: Suppression of well-established tumour xenografts by a hybrid-hybrid monoclonal antibody and vinblastine 157
Sondel PM → Hank JA
Sosman JA → Hank JA
Steerenberg PA → De Jong WH
Steerenberg PA, De Jong WH, Geerse E, Beuvink A, Scheper RJ, Den Otter W, Ruitenberg EJ: Major-histocompatibility-complex-class-II-positive cells and interleukin-2-dependent proliferation of immune T cells are required to reject carcinoma cells in the guinea pig 297
Stimson WH → Gallagher G
Stricker H → Matzku S
Strijk S → Mulder PHM de
Stuber G, Vánky F, Pócsik E, Benczúr M, Klein E: Expression of interleukin-2 receptor on blood lymphocytes stimulated with allogeneic lymphocytes or autologous tumor cells. The mixed lymphocyte culture of allo-sensitized individuals and the auto-tumor stimulation show similar kinetics of activation 76
Surfus JE → Hank JA
Sutherland F, Borkenhagen K, Temple L, Bryant LD, Lafreniere R: Effects of cyclosporin on C57BL/6 splenocytes before and after culture with high-dose recombinant interleukin-2: implications for immunosuppression with cyclosporin 312

Takeichi N, Li X, Hamada J-i, Kobayashi H: Age-related decrease of pulmonary metastasis of rat mammary carcinoma by activated natural resistance 81
Takesue M → Torisu M
Tamagake T → Sasaki J-i
Tatake RJ → Rajaram N
Temple L → Sutherland F
Testa U, Care A, Montesoro E, Fossati C, Giannella G, Masciulli R, Fagioli M, Bulgarini D, Habetswallner D, Isacchi G, Pelicci PG, Tichatschek E → Rasoul-Rockenschaub S
Toivanen A → Valavaara R
Torisu M, Hayashi Y, Ishimitsu T, Fujimura T, Iwasaki K, Katano M, Yamamoto H, Kimura Y, Takesue M, Kondo M, Nomoto K: Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer 261
Tuominen J → Valavaara R
Turk TMT → Hoover SK

Uchida A, Fujimoto T, Mizutani Y: Lysing of fresh human tumor by a cytotoxic factor derived from autologous large granular lymphocytes independently of other known cytokines 60
Uppenkamp M → Belldegrun A

Valavaara R, Tuominen J, Toivanen A: The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene 381
Van der Meijden APM → De Jong WH
Vánky F, Wang P, Patarroyo M, Klein E: Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro 19
Vánky F → Stuber G
Vegt P → De Jong WH
Vorechovsky I, Litzman J, Lokaj J, Hausner P, Poch T: Common variable immunodeficiency and malignancy: a report of two cases and possible explanation for the association 250
Wagner JG → Barrett JS

Wahl RL → Barrett JS
Waldmann H → Weiss L
Wallack MK → Arroyo PJ
Wang P → Vánky F
Weckenmann H-P → Matzku S
Weigensberg M → Weiss L
Weil-Hillman G → Hank JA
Weiskirch LM, Barker E, Mokyr MB: Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt 2^+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor 129
Weiss L, Weigensberg M, Morecki S, Bar S, Cobbold S, Waldmann H, Slavin S: Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia 236
Wersäll P → Masucci G
Wesp M → Landmann R
West WH → Winkler MA
Winkler MA, Price JO, Foglesong PD, West WH: Biodistribution and plasma survival in mice of anti-melanoma monoclonal antibody cross-linked to OKT3 278
Wong L-C → Ho P-C

Yamamoto H → Torisu M
Yamasaki H, Okamoto E, Komatsu T, Manabe Y, Shinka S: Relationship between general or specific immunoreactivity and prognosis in postoperative patients with hepatocellular carcinoma 107
Yano I → Natsuhara Y
Ybarrondo B → Chong AS-F
Yoshida T → Ding L-N

Zielinski CC → Rasoul-Rockenschaub S